Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (391-400 of 483) with videos related to

Pageof 49
Sort By:
Haematologica|January 22, 2026
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in EuropeMichele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, et al.
Journal of Hematology & Oncology|April 17, 2016
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classificationsLisa Pleyer, Sonja Burgstaller, Reinhard Stauder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive ScoreBarbara Burtness, Danny Rischin, Richard Greil, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2020
Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trialGerd Fastner, Felix Sedlmayer, Joachim Widder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 StudyKevin J Harrington, Barbara Burtness, Richard Greil, et al.
Therapeutic Advances in Medical Oncology|April 22, 2020
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: <i>post hoc</i> analysis of an Austrian multicenter, noninterventional studyJakob Michael Riedl, Florian Posch, Gerald Prager, et al.
The Lancet. Oncology|September 1, 2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 studyTiciana Leal, Rupesh Kotecha, Rodryg Ramlau, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialThorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2013
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancerJohn P Crown, Véronique Diéras, Elzbieta Staroslawska, et al.
Pageof 49

Showing results (391-400 of 483) with videos related to

Sort By:
Pageof 49
Haematologica|January 22, 2026
Real-world effectiveness and safety of belantamab mafodotin monotherapy in patients with relapsed/refractory multiple myeloma treated in EuropeMichele Cavo, Fredrik Schjesvold, Meletios Dimopoulos, et al.
Journal of Hematology & Oncology|April 17, 2016
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classificationsLisa Pleyer, Sonja Burgstaller, Reinhard Stauder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2022
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive ScoreBarbara Burtness, Danny Rischin, Richard Greil, et al.
Cancers|May 28, 2022
Adverse Events in 1406 Patients Receiving 13,780 Cycles of Azacitidine within the Austrian Registry of Hypomethylating Agents-A Prospective Cohort Study of the AGMT Study-GroupMichael Leisch, Michael Pfeilstöcker, Reinhard Stauder, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2020
Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trialGerd Fastner, Felix Sedlmayer, Joachim Widder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2022
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 StudyKevin J Harrington, Barbara Burtness, Richard Greil, et al.
Therapeutic Advances in Medical Oncology|April 22, 2020
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: <i>post hoc</i> analysis of an Austrian multicenter, noninterventional studyJakob Michael Riedl, Florian Posch, Gerald Prager, et al.
The Lancet. Oncology|September 1, 2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 studyTiciana Leal, Rupesh Kotecha, Rodryg Ramlau, et al.
The Lancet. Oncology|October 30, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trialThorsten Fuereder, Javier Garde-Noguera, Juan José García-Mosquera, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2013
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancerJohn P Crown, Véronique Diéras, Elzbieta Staroslawska, et al.
Pageof 49